Predictors of increased melphalan exposure correlate with overall survival, nonrelapse mortality, and toxicities in patients undergoing reduced-intensity allogeneic stem cell transplantation with fludarabine and melphalan.
作者： Karen Sweiss , Gregory Sampang Calip , Jaime Holden , Paulina Lewkowski , Iryna Mialik
关键词:
摘要: The reduced-intensity conditioning regimen, fludarabine and melphalan 140 mg/m2 (FM140), is widely adopted in practice. Pharmacokinetic studies report 10-fold interpatient variability ...
sagepub.com
sci-hub.st 参考文章(35)
Bressolle F, Pinguet F, Fabbro M, Culine S, Martel P, Astre C, Petit I, Canal P, Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation. Anticancer Research. ,vol. 17, pp. 605- 611 ,(1997)
J L Harousseau, C Larousse, N Milpied, P Moreau, M F Kergueris, Pharmacokinetics of high-dose melphalan in adults: influence of renal function. Anticancer Research. ,vol. 14, pp. 2379- 2382 ,(1994)
Donald W. Cockcroft, Henry Gault, Prediction of Creatinine Clearance from Serum Creatinine Nephron. ,vol. 16, pp. 31- 41 ,(1976) , 10.1159/000180580
Christa E. Nath, Peter J. Shaw, Judith Trotman, Lihua Zeng, Stephen B. Duffull, Gareth Hegarty, Andrew J. McLachlan, Howard Gurney, Ian Kerridge, Yiu Lam Kwan, Peter Presgrave, Campbell Tiley, Douglas Joshua, John Earl, Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy British Journal of Clinical Pharmacology. ,vol. 69, pp. 484- 497 ,(2010) , 10.1111/J.1365-2125.2010.03638.X
I F Khouri, M Keating, M Körbling, D Przepiorka, P Anderlini, S O'Brien, S Giralt, C Ippoliti, B von Wolff, J Gajewski, M Donato, D Claxton, N Ueno, B Andersson, A Gee, R Champlin, Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. Journal of Clinical Oncology. ,vol. 16, pp. 2817- 2824 ,(1998) , 10.1200/JCO.1998.16.8.2817
B L Samuels, J D Bitran, High-dose intravenous melphalan: a review. Journal of Clinical Oncology. ,vol. 13, pp. 1786- 1799 ,(1995) , 10.1200/JCO.1995.13.7.1786
A Gratwohl, , H Baldomero, J Passweg, A Urbano-Ispizua, Increasing use of reduced intensity conditioning transplants: report of the 2001 EBMT activity survey. Bone Marrow Transplantation. ,vol. 30, pp. 813- 831 ,(2002) , 10.1038/SJ.BMT.1703819
P J Shaw, C E Nath, H M Lazarus, Not too little, not too much-just right! (Better ways to give high dose melphalan). Bone Marrow Transplantation. ,vol. 49, pp. 1457- 1465 ,(2014) , 10.1038/BMT.2014.186
R K Dasgupta, S Rule, P Johnson, J Davies, A Burnett, C Poynton, K Wilson, G M Smith, G Jackson, C Richardson, E Wareham, A C Stars, S M Tollerfield, G J Morgan, Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect Bone Marrow Transplantation. ,vol. 37, pp. 455- 461 ,(2006) , 10.1038/SJ.BMT.1705271
Sarayut Janmahasatian, Stephen B Duffull, Susan Ash, Leigh C Ward, Nuala M Byrne, Bruce Green, Quantification of lean bodyweight Clinical Pharmacokinectics. ,vol. 44, pp. 1051- 1065 ,(2005) , 10.2165/00003088-200544100-00004